Financials in USD. Standardized financial statements.
A compact view of how Anika Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $112.82M | $119.91M | $120.79M | $113.83M | $147.79M | $130.46M | $114.61M | $105.56M | $113.42M | $103.38M |
| Revenue Growth? | -5.9% | -0.7% | +6.1% | -23.0% | +13.3% | +13.8% | +8.6% | -6.9% | +9.7% | 0.0% |
| Cost of Revenue? | $49.01M | $43.91M | $38.26M | $40.61M | $64.85M | $61.43M | $28.75M | $31.28M | $27.36M | $24.03M |
| Gross Profit? | $63.81M | $76.00M | $82.53M | $73.22M | $82.94M | $69.03M | $85.86M | $74.28M | $86.06M | $79.35M |
| Gross Margin? | +56.6% | +63.4% | +68.3% | +64.3% | +56.1% | +52.9% | +74.9% | +70.4% | +75.9% | +76.8% |
| Operating Expenses? | $74.86M | $81.10M | $81.69M | $69.55M | $80.33M | $97.35M | $51.62M | $52.53M | $40.33M | $28.75M |
| Operating Income? | -$11.05M | -$5.10M | $844,000 | $3.67M | $2.62M | -$28.32M | $34.25M | $21.75M | $45.73M | $50.61M |
| EBITDA? | -$5.32M | $3.02M | $15.06M | $18.16M | -$4.16M | -$1.00M | $40.24M | $27.66M | $50.02M | $54.34M |
| Income Before Tax | -$9.31M | -$2.76M | $3.16M | $4.32M | $2.43M | -$28.62M | $36.12M | $23.21M | $46.20M | $50.87M |
| Income Tax Expense | $672,000 | $6.06M | $6.59M | $2.12M | -$1.71M | -$4.64M | $8.93M | $4.49M | $14.39M | $18.32M |
| Net Income? | -$10.88M | -$56.38M | -$82.67M | -$14.86M | $4.13M | -$23.98M | $27.19M | $18.72M | $31.82M | $32.55M |
| EPS? | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.29 | $-1.69 | $1.93 | $1.30 | $2.18 | $2.22 |
| Diluted EPS? | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality